Strong and effective regulatory monitoring of drug safety requires the rapid reporting of adverse reactions following vaccinations or drug administration. If such reports accumulate, the authorities should respond by stopping or restricting the drug, if necessary. Reports can also help to detect contaminated medicines more quickly and inform the public…
Context Tuberculosis remains one of the world’s deadliest infectious diseases and is closely linked to low socioeconomic and poor sanitary conditions. The increasing emergence of tuberculosis strains resistant to key medicines poses a serious threat to global tuberculosis control. In many countries with a high disease burden, rapid diagnostic methods…
Context Antimicrobial resistance occurs when antibiotics lose their effectiveness against bacterial infections. It is a growing public health concern, particularly in sub-Saharan Africa. Key contributing factors include uncontrolled access to antibiotics, inappropriate use in human and animal medicine, and limited access to laboratory-based diagnostics. Many rural areas lack adequate laboratory…
Context Natural and (un-)intentional disease outbreaks pose major risks. Effective outbreak management and compliance with International Health Regulations require a skilled, well-trained workforce. Innovative, sustainable training initiatives are needed to strengthen competency and capacity. The FOR-GHP project uses a multiplier approach to enhance health emergency preparedness, response, and resilience among…
This page is currently under development. An overview of the project will be published shortly. In the meantime, you are welcome to visit https://ghpp.de/en/projects/ for information about further projects within the GHPP. Thank you for your patience. Facts 01.01.2026 - 31.12.2028…
Context Rising outbreaks of infectious diseases, growing antimicrobial resistance and chronic diseases pose major challenges to health systems worldwide. Strong, well-functioning medicines regulatory authorities help ensure that people can access safe, effective and quality-assured medicines and vaccines in time. This supports a reliable drug supply and reduces pressure on healthcare…
Context In many countries in Western and South-Eastern Africa, access to safe and effective medicines remains a challenge. A key factor is the limited capacity of national drug quality control laboratories. Insufficient structures, resources or standardised procedures hinder reliable quality testing. As a result, substandard or falsified medicines may reach…
The BloodTrain Next Generation team trained twelve regulators from six African medicines regulatory authorities at the Paul-Ehrlich-Institut (PEI) from 20 to 31 October 2025. The participants deepened their knowledge in the regulation of blood screening in vitro diagnostic medical devices (IVDs) through practical training with PEI IVD experts. They particularly…
Great efforts are being made to increase vaccine production in Africa. Local drug regulatory authorities are responsible for testing vaccine batches for quality, safety, and efficacy. They approve them for human use. The VaccRelease project of the Paul-Ehrlich-Institut (PEI) supports its partner countries in Africa in setting up an effective…